Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals SPPI
report update icon

Quarterly report 2023-Q1
added 11-21-2026

Spectrum Pharmaceuticals Net Debt | SPPI

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Spectrum Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
-10.9 M -85.8 M -43.6 M -60.4 M -157 M -189 M -61.2 M -38.2 M -33.6 M -64.8 M -64.7 M -121 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-10.9 M -189 M -77.6 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Omeros Corporation Omeros Corporation
OMER
84 M $ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-2.04 M $ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
-39.4 M - 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
-44.7 M - - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
-19.9 M - - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
202 M - - $ 26.6 B irlandaIrlanda
Provention Bio Provention Bio
PRVB
-20.4 M - - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
77.2 M - - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-7.94 M $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
-137 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-5.46 M $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
-11 M - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
-59.7 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
-85.6 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-141 M $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
-80.1 M $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
-1.16 M - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
-23.8 M - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
707 K - -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
-4.58 M - -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
56.3 M $ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
-8.39 M - -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
-2.55 M - -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
-52.4 M - -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
122 M - - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
-214 M - -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
452 K - -48.37 % $ 3.71 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
-7.19 M - - $ 4.55 M irlandaIrlanda
Annovis Bio Annovis Bio
ANVS
-8.07 M $ 0.71 -3.81 % $ 14.6 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
-24.1 M - - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
-51.9 M - - $ 105 M usaUSA
Athersys Athersys
ATHX
-353 K - 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
-433 M - - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
11.3 M - - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
120 M - -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
-45 M - -81.12 % $ 4.28 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
-13.6 M $ 3.56 -9.07 % $ 1.58 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
9.38 M - -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
-20.5 M - - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
-104 M - -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
-1.36 M - -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
-7.95 M - -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
-141 M - - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
-5.52 M $ 0.93 -4.11 % $ 10.5 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
-24.8 M $ 1.89 6.78 % $ 52.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
131 M - -24.86 % $ 820 K usaUSA
Longeveron Longeveron
LGVN
-3.84 M $ 1.65 -9.34 % $ 29 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Immunic Immunic
IMUX
-14.9 M $ 7.0 -5.28 % $ 1.09 B usaUSA